Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Keytruda is currently indicated in a variety of cancers ... “surpassing traditional checkpoint inhibitors.” Thus far, ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... Akeso and Summit are leading the race, but BioNTech is well ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...

The company said BNT327/PM8002 had demonstrated encouraging clinical results in more than 700 patients, with registrational ...

Zelnecirnon was being evaluated in two randomized, placebo-controlled Phase 2 clinical trials in asthma and atopic dermatitis, and both trials were placed on clinical hold by the U.S. Food and Drug ...